Takeda receives approval from european commission for fruzaqla in previously treated metastatic colorectal cancer

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the european commission (ec) approved fruzaqla (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents, and who have progressed on or are intolerant to.
TAK Ratings Summary
TAK Quant Ranking